TGFB1 and glioblastoma: Meanwhile, SNHG20 also elevated tumor progression by controlling the epithelial-to-mesenchymal transition (EMT) signaling pathway in osteosarcoma or hepatocellular carcinoma [23, 24, 31], activating PI3K/Akt/mTOR pathway in glioblastoma [25], as well as upregulating the expression of transforming growth factor-β1 (TGF-β1) in nasopharyngeal carcinoma [18], etc. Given these above molecular mechanisms of SNHG20 among various carcinomas, it was obvious that SNHG20 was connected with an unfavorable prognosis in cancer patients, which further provided support for clinical utility of SNHG20.